by divibasicbldev | Aug 18, 2022 | Press Releases
— Annual “From Laboratory to Clinic” conference, held at Trinity College, Oxford University, explores latest discoveries in immunology and molecular medicine —- PAS002 is a proprietary DNA vaccine construct encoding GlialCAM — MIAMI...
by divibasicbldev | Aug 11, 2022 | Press Releases
— PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM —- PAS002 effectively reduces disease severity, delays onset of illness, while also reducing relapse severity —- GlialCAM fragment is present in monkeypox virus, supporting...
by divibasicbldev | Aug 2, 2022 | Press Releases
Stockholders Should Protect Upside in Potential Groundbreaking Therapies for MS, ALS and Other Large Unmet Medical Conditions from Activist’s Apparent Cash Grab Board Unanimously Recommends Stockholders to Sign, Date and Return GOLD Consent Revocation Card MIAMI...
by divibasicbldev | Jul 14, 2022 | Press Releases
— AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction —- Provides approximately U.S. $694,000 of non-dilutive funding — MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp....
by divibasicbldev | Jun 23, 2022 | Press Releases
MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for...
by divibasicbldev | Jun 22, 2022 | Press Releases
– Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases — Expands pipeline across Pasithea’s core therapeutic areas to drive enhanced growth —...
